Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270482 | 0.84 | HRH3 (0.41) | GRM2HRH3SLC6A4 | |
| SCHEMBL3273836 | 0.83 | HRH3 (0.48) | GRM2HRH3SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3270604 | 0.81 | HRH3 (0.48) | GRM2HRH3SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3274822 | 0.80 | SLC6A4 (0.41) | GRM2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3272110 | 0.80 | HRH3 (0.51) | HRH3SLC6A4SLC6A3 | |
| SCHEMBL3276863 | 0.78 | SLC6A4 (0.38) | HRH3SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3271618 | 0.77 | HRH3 (0.53) | HRH3SLC6A4SLC6A3 | |
| SCHEMBL3277203 | 0.76 | HRH3 (0.41) | GRM2HRH3 | |
| SCHEMBL3271908 | 0.75 | KDM4E (0.47) | GRM2HRH3 | |
| SCHEMBL3271784 | 0.73 | LMNA (0.48) | HRH3SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | claimed |
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | ZIARCO INC. | 2005-12-01 | — | — | US | claimed |
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | ZIARCO INC. | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | HRH4, HRH3, TLR4 | GRM2 2116/4885HRH3 2/4885SLC6A4 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.